William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on LENZ stock, giving a Buy rating on September 17.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors surrounding the recent developments at LENZ Therapeutics. The company has achieved a significant milestone with the commercial availability of its product, Vizz, in the U.S. This marks a pivotal transition for LENZ into a commercial-stage company, which is a positive indicator for its growth potential. The early availability of Vizz, ahead of initial expectations, demonstrates the company’s strong execution capabilities and readiness for a successful product launch.
Moreover, Vizz is positioned with a best-in-class profile for the presbyopia market, which remains largely untapped. Despite previous challenges in this space, Vizz’s differentiated efficacy and durability offer a promising outlook for its success. Although substantial revenue is not anticipated until early 2026 due to the current sampling strategy and phased retail availability, the early launch metrics and engagement with eye care professionals are expected to provide valuable insights for investors. These factors collectively underpin the Buy rating, reflecting confidence in the company’s strategic direction and market potential.
In another report released on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $56.00 price target.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LENZ in relation to earlier this year.